BI 730357 PoCC and dose-ranging in Psoriasis
Research payments
$178,082
Through program year 2021, $178,082 in research payments was reported against BI 730357 PoCC and dose-ranging in Psoriasis, across 466 payments.
- Paid by (largest first)
- Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharma GmbH & Co.KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $8,126 | 17 |
| 2020 | Research | $80,698 | 123 |
| 2019 | Research | $89,258 | 326 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Howard Sofen Los Angeles, CA Named on 37 payments
- Stephen Tyring Webster, TX Named on 37 payments
- James Krell Birmingham, AL Named on 36 payments
- Jerry Bagel East Windsor, NJ Named on 32 payments
- Martin Menter Dallas, TX Named on 32 payments
- Ellen Frankel Cranston, RI Named on 30 payments
- Tiffani Hamilton Alpharetta, GA Named on 26 payments
- Jamie Weisman Atlanta, GA Named on 26 payments
- Richard Beasley Rapid City, SD Named on 25 payments
- David Pariser Norfolk, VA Named on 25 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.